Palisade Bio director buys 30,000 shares

Palisade Bio director Robert Baltera Jr. bought a total of 30,000 shares of Palisade Bio common stock in open-market transactions, paying $1.98 per share.

Rhea-AI Filing Summary

Palisade Bio director Robert Baltera Jr. bought a total of 30,000 shares of Palisade Bio common stock in open-market transactions, paying $1.98 per share. The purchases occurred over two days and increased his direct holdings to 366,904 shares.

The filing notes that the reported price is a weighted average, with individual trades executed between $1.97 and $1.99 per share. These transactions represent additional personal investment in the company by a board member, rather than option exercises or compensation-related grants.

Insider Trade Summary

Net Buyer: 30,000 shares

Net Buy 2 txns

Insider Baltera Robert Jr.

Role Director

Bought 30,000 shs ($59K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.98	$20K
Purchase	Common Stock	20,000	$1.98	$40K

Holdings After Transaction: Common Stock — 366,904 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 30,000 shares Purchase price: $1.98 per share Price range: $1.97–$1.99 per share +2 more

5 metrics

Shares purchased 30,000 shares Total open-market buys reported in Form 4

Purchase price $1.98 per share Reported transaction price for both purchases

Price range $1.97–$1.99 per share Weighted-average footnote trade range

Shares owned after 366,904 shares Director’s direct holdings following transactions

Number of buy transactions 2 transactions Open-market purchases of common stock

Key Terms

open-market purchase, weighted average price, Reporting Person, Form 4

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Reporting Person regulatory

"The Reporting Person undertakes to provide to the Issuer"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Palisade Bio (PALI) report in this Form 4?

The Form 4 shows director Robert Baltera Jr. made two open-market purchases totaling 30,000 Palisade Bio common shares at $1.98 each, increasing his direct ownership position to 366,904 shares following the transactions.

At what prices did the Palisade Bio (PALI) director buy shares?

The director’s reported purchase price was a weighted average of $1.98 per share. A footnote explains the actual trades were executed in multiple transactions at prices ranging from $1.97 to $1.99 per Palisade Bio common share.

How many Palisade Bio (PALI) shares does Robert Baltera Jr. hold after the trades?

After buying 30,000 additional shares, director Robert Baltera Jr. directly holds 366,904 shares of Palisade Bio common stock. This total reflects his position immediately following the reported open-market purchases disclosed in the Form 4 filing.

Were the Palisade Bio (PALI) insider transactions open-market purchases or option exercises?

The transactions were open-market purchases of common stock, not option exercises. The Form 4 uses transaction code “P” and describes them as purchases in open-market or private transactions, with no derivative securities listed in the derivative summary.

How many insider share purchases were reported for Palisade Bio (PALI) in this filing?

The filing reports two separate insider purchase transactions. Together they account for 30,000 Palisade Bio common shares bought by director Robert Baltera Jr., with no reported sales, gifts, tax withholdings, or derivative exercises in this specific Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 07:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baltera Robert Jr.

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		P		20,000	A	$1.98(1)	356,904	D
Common Stock	07/02/2026		P		10,000	A	$1.98(1)	366,904	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Ryker Willie, Attorney-in-Fact for Robert Baltera Jr.	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)